This has increased the therapeutic efficacy and safety
profiles of these medicines, resulting in significant nucleic acid
therapeutics market development.
WILMINGTON, Del., Aug. 1, 2024
/PRNewswire/ -- According to Transparency Market Research, the
scope for nucleic acid therapeutics is immense in the forthcoming
decade. With an astounding CAGR of 12.8%, the market is
forecast to attain a valuation of US$ 22.1 billion by 2034. As of 2023,
the nucleic acid therapeutics landscape was valued at US$ 6 billion.
Advances in genetic research and biotechnology are propelling
the nucleic acid therapeutics market value. These medicines, which
include antisense oligonucleotides (ASOs), RNA interference (RNAi),
and RNA aptamers, provide targeted treatments for a range of
genetic abnormalities, infectious diseases, and malignancies.
Download Sample of the Report:
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86333
ASOs have the largest market share due to their strong
therapeutic properties; they are effective in treating rare genetic
disorders such as Duchenne muscular dystrophy and spinal muscular
atrophy. RNAi medicines, with their great specificity in gene
silencing, are expected to witness substantial market progress,
fueled by successful drugs such as patisiran and givosiran. RNA
aptamers, albeit being rare, show great potential because of their
unique targeting capabilities.
The creation of synthetic oligonucleotides has resulted in
substantial advances in nucleic acid treatments. To improve their
medicinal capabilities, synthetic oligonucleotides undergo certain
chemical changes. These alterations can take place at three
different sites: the nucleobase, the ribofuranose unit, and the
phosphate backbone.
Altering the nucleobase and ribose units can shield
oligonucleotides against enzymatic damage, thus enhancing their
stability within the body, whereas modification of the phosphate
backbone can make nucleotide chains less negatively charged, thus
promoting their cellular uptake and target localization.
Nucleic Acid Therapeutics Market Report Scope:
Report
Coverage
|
Details
|
Forecast
Period
|
2024-2034
|
Base
Year
|
2020-2022
|
Size in 2023
|
US$ 6.0 Bn
|
Forecast (Value) in
2034
|
US$ 22.1 Bn
|
Growth Rate
(CAGR)
|
12.8 %
|
No. of
Pages
|
195
Pages
|
Segments
covered
|
By Product, By
Indication, By End-user, By Region
|
Competitive Landscape
The market for nucleic acid therapeutics is highly competitive
and has a strong presence of key players. The nucleic acid
therapeutics market report highlights that leading players are
adopting strategies such as acquisition and launch of new products.
Key players operating in the nucleic acid therapeutics domain
include:
- Alynylam Pharmaceutials Inc.
- BioNTech
- Ionis Pharmaceuticals Inc.
- Moderna
- Nippon Shinyaku
- Novartis
- Pfizer
- Sarepta Therapeutics
- Biogen Inc.
- Genzyme Sanofi
- Percheron Therapeutics Ltd.
- Other Prominent Players
Key Market Developments
- In April
2024, autogene cevumeran, an RNA-based
cancer treatment that stimulates the immune system to target and
kill pancreatic cancer cells, was investigated in a clinical trial
by the Memorial Sloan Kettering Cancer Center. This stops existing
cancer as well as avoids more illness with the help of a strong
immune system.
- In December
2023, Ionis Pharmaceuticals expanded
its Carlsbad's facility for improving its nucleotide-based
therapeutics capabilities, expecting support for product investment
as well as clinical trials so as bring in more innovative
nucleotide drugs into the market, which constitutes the main theme
of its antisense technology.
Key Takeaways from the Market Report
- In 2024, the nucleic acid therapeutics market is expected to
total US$ 6.8 billion.
- From 2024 to 2034, the market is anticipated to expand
3.2x.
- By product, demand for anti-sense oligonucleotides (ASO) is
expected to be high, attributed to their capacity to specifically
target and modify gene expression.
- By indication, genetic disorders are expected to be primary
areas for nucleic acid therapeutics.
Key Market Drivers and Trends
- Modifications of chemical structure of genes address the
fundamental constraints of native oligonucleotides, which include
low stability and poor physicochemical characteristics.
- As a result, these changes vividly improve the pharmacokinetic
characteristics of oligonucleotide-based treatments, making them
more promising for clinical usage.
- Because of their increased stability and efficiency, nucelic
acid based drugs can now be used to treat a wide spectrum of
ailments, including genetic abnormalities and malignancies.
- Hence, improved efficacy and safety profiles of the new
synthetic oligonucleotides and innovative gene editing technologies
are fueling the nucleic acid therapies market size.
Explore Sample of the Report:
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86333
Regional Profile
- North America promises to
yield significant expansion opportunities for nucleic acid
therapeutics. Excellent research and development
infrastructure, robust regulatory environment, and high prevalence
of genetic abnormalities and diseases treated with these therapies
are driving market dynamics.
- The United States, in
particular, is home to prominent biotechnology and pharmaceutical
businesses that invest in cutting-edge technologies such
as CRISPR-Cas gene editing and synthetic
oligonucleotides. The region's well-established regulatory
system, which includes clear standards from agencies such as the
FDA, promotes innovation and supports the timely launch of
innovative treatments.
- Good legislation and more clinical trials are driving the
nucleic acid therapeutics market revenue in Europe. Furthermore, with improved
technology and access to better healthcare, Asia Pacific is becoming a lucrative
market.
Key Segments Profiled
Product
- Anti-sense Oligonucleotides (ASO)
- RNA Interference (RNAi)
- RNA Aptamers
Indication
- Autoimmune Disorders
- Infectious Diseases
- Genetic Disorders
- Cancer
- Others (Neurodegenerative Diseases, etc.)
End User
- Hospitals
- Physicians' Offices
- Others (Academics and Research Institutes, etc.)
Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East &
Africa
Buy this Premium Research Report:
https://www.transparencymarketresearch.com/checkout.php?rep_id=86333<ype=S
More Trending Report by Transparency Market Research:
- Operating Room Integration Market - With a projected
CAGR of 13.9% for the next ten years, the market is likely to reach
a valuation of nearly US$ 7.2 Bn by
the end of 2032.
- Near Infrared Imaging Market - Preclinical
Imaging is expected to be the highest revenue-generating
application, projected to grow at a CAGR of over 14.2% during 2022
– 2032.
- Single-use Flexible Endoscope Market is projected to
advance at a CAGR of 23.9% between 2022 and 2031 and reach more
than US$ 9.1 Bn by the end of
2031
About Transparency Market Research
Transparency Market Research, a global market
research company registered at Wilmington, Delaware, United States, provides custom research and
consulting services. Our exclusive blend of quantitative
forecasting and trends analysis provides forward-looking insights
for thousands of decision makers. Our experienced team of Analysts,
Researchers, and Consultants use proprietary data sources and
various tools & techniques to gather and analyses
information.
Our data repository is continuously updated and revised by a
team of research experts, so that it always reflects the latest
trends and information. With a broad research and analysis
capability, Transparency Market Research employs rigorous primary
and secondary research techniques in developing distinctive data
sets and research material for business reports.
Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER
DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware
19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free:
866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com
Follow Us:
LinkedIn | Twitter | Blog | YouTube
Logo:
https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/nucleic-acid-therapeutics-market-to-reach-usd-22-1-billion-by-2034--advances-in-genetic-research-and-biotechnology-propel-growth-transparency-market-research-inc-302212226.html
SOURCE Transparency Market Research